Slide 1: Inspiring the World to Move Well – Investor Update January 2017
// 1 For personal use only INSPIRING THE WORLD TO MOVE WELL INVESTOR UPDATE JANUARY 2017
Slide 2: Disclaimer
DISCLAIMER // 2 This presentation does not constitute investment, legal, taxation or other advice and the For personal use only presentation does not take into account your investment objectives, financial situation or particular needs. You are responsible for forming your own opinions and conclusio
Slide 3: Agenda
// 3 AGENDA For personal use only INSPIRING THE WORLD TO MOVE WELL™ • About dorsaVi REVOLUTIONARY • Operational update WEARABLE SENSOR TECHNOLOGY • ViSafe overview • ViMove overview • ViPerform overview • Outlook
Slide 4: About dorsaVi
For personal use only About dorsaVi // 4
Slide 5: Timeline
© dorsaVi | Timeline a 1995 | 2000 + Andrew Ronchi + Sensor prototype began contemplating development begins developing a The medical device dorsaVi technology established using government grants, by Andrew and Dan ry that underpins > 2004 2006 + dorsaVi wired proto + Patent protection released Ronc
Slide 6: Board and Senior Management
BOARD AND SENIOR MANAGEMENT // 6 For personal use only Chairman Non Executive Director Non Executive Director Non Executive Director Herb Elliott Greg Tweedly Michael Panaccio Ash Attia Director & CEO Andrew Ronchi CFO CIO CPO CMO Head of Sales and Head of Sales and Head of Sales and Damian Connella
Slide 7: Our Business: Solid Foundation for Growth
OUR BUSINESS: SOLID FOUNDATION FOR GROWTH // 7 • Three key business divisions with diversified revenue streams For personal use only • Organisational health and safety • Clinical • Elite sports • Market leader with first mover advantage • Patent protected technology • Significant barriers to entry a
Slide 8: The Hardware and Products
THE HARDWARE AND PRODUCTS // 8 For personal use only • OHS solution to determine, measure and mitigate high risk activities • Patent protected movement algorithms • Significant appetite for innovative manual handling solutions on medical-grade sensor technology • Executive and board-level focus on r
Slide 9: For personal use only
ef Allianz @ 6 bhpbilliton \WWorksWell lz MONASH tethered ~~ University Hiscjormoce SURGE ATHLETIC PERFORMANCE ONE Wy. HAWKS pt thy _ La Naar? emeen DOCKERS wig
Slide 10: Operational Update
// 10 For personal use only Operational Update
Slide 11: Financial Overview
FINANCIAL OVERVIEW // 11 dorsaVi Customer Revenue For personal use only 2013 2014 2015 2016 H1 2017 3,000 Revenue 398,607 529,380 1,358,218 3,019,000 1,730,000* EBITDA (2,148,749) (3,852,593) (8,684,709) (5,915,567) N/A 2,500 1,008 Loss from (1,659,235) (3,562,024) (8,036,161) (5,237,102) N/A contin
Slide 12: Strong Global Growth
STRONG GLOBAL GROWTH // 12 dorsaVi Sales Revenue For personal use only $2.0M $1.8M $1.6M $1.4M $1.2M Q4 $1.0M Q3 Q2 $0.8M Q1 $0.6M $0.4M $0.2M $0.0M FY2015 FY2016 FY2017 FY2015 FY2016 FY2017 FY2015 FY2016 FY2017 AU UK US
Slide 13: Business Maturing: Improving Key Business Metrics
BUSINESS MATURING: IMPROVING KEY BUSINESS METRICS // 13 Sales Revenue (AUD) Total Expenses excl. COGS (AUD) Operating Loss before tax (AUD) For personal use only 2,000 4,500 $4,147,000 $1,729,000* 5 1,800 4,000 4.5 1,600 3,500 $3,253,000** 4 1,400 $3.3m $1,292,000 725 2,036 3,000 3.5 1,200 1348 3 2,
Slide 14: Execution Across the Product Lines
EXECUTION ACROSS THE PRODUCT LINES // 14 ViSafe (OHS) For personal use only • ViSafe continues to grow across all three geographic markets • Launched myViSafe™ - new ViSafe solution which will generate annuity revenue • Three myViSafe customers signed in December ViMove (Clinical) • Beachhead Client
Slide 15: Reducing Costs & Injury, Improving Productivity, Building Safety Culture
// 15 For personal use only REDUCING COSTS & INJURY IMPROVING PRODUCTIVITY BUILDING SAFETY CULTURE INSPIRING THE WORLD TO MOVE WELL™
Slide 16: For personal use only
For personal use only // 16
Slide 17: Scalable Revenue Model
// 17 SCALABLE REVENUE MODEL For personal use only $40,000 $100,000 $300,000 Risk Assessment Solution Implementation Long Term Annuity Monitor Workforce
Slide 18: Annuity Revenue Introduced
// 18 ANNUITY REVENUE INTRODUCED For personal use only • Launched in December 2016 • Three customers signed up • Self-managed solution with ongoing revenue stream • Complementary to other ViSafe offerings
Slide 19: Launched Agent Model for Rapid Revenue Growth
// 19 LAUNCHED AGENT MODEL FOR RAPID REVENUE GROWTH For personal use only Scalable model: • Direct sales representatives in key markets • Sales partnerships with agents (win work & provide assessors) • Insurers and Insurance Brokers • Centralised analysis
Slide 20: FDA Cleared, CE Mark, TGA Supported by Clinical Trial Data
// 20 For personal use only FDA CLEARED, CE MARK, TGA SUPPORTED BY CLINICAL TRIAL DATA INSPIRING THE WORLD TO MOVE WELL™
Slide 21: US Health Market Looking for Cost Saving
// 21 US HEALTH MARKET LOOKING FOR COST SAVING For personal use only Healthcare technology will reduce the burden on $560B health systems globally by: • Improving decision making & timely intervention • Allowing point-of-care diagnosis and treatment • Safe and clinically proven care • Personalised t
Slide 22: Clinical Trial Shows Treatment and Cost Benefit
CLINICAL TRIAL SHOWS TREATMENT AND COST BENEFIT // 22 Clinical Treatment Benefit Economic/Cost Benefit For personal use only “This evaluation has identified that motion-sensor biofeedback intervention using ViMove system was both more effective and less costly overall than the control from the socie
Slide 23: Significant Untapped Opportunity
SIGNIFICANT UNTAPPED OPPORTUNITY // 23 380 devices in the market For personal use only 160 devices in the market 24,000 physios (0.5% penetration) 90 devices in the market 130 devices in the market 48,000 physios 284,000 physical therapists
Slide 24: Clinical Platform to Manage Data, Reports and Communication
// 24 CLINICAL PLATFORM TO MANAGE DATA, REPORTS AND COMMUNICATION For personal use only Insurer PATIENT REPORTS AND DATA $ Doctor Employer Patient Specialist Physio Hospital Live Assessment Live Training Monitoring Biofeedback Exercises Reports
Slide 25: Clinical Sales and Revenue Model
// 25 CLINICAL SALES AND REVENUE MODEL For personal use only Targeting large and company-owned franchise networks • UK – YPP • USA – MeyerPT • Relationship with Select Medical (pilot with 20 of their 2,000 sites) Collaborative product developments • Product currently commercially released: ViPerform
Slide 26: Planned Product Releases on New Sensor Platform
// 26 PLANNED PRODUCT RELEASES ON NEW SENSOR PLATFORM For personal use only New cloud-based New cloud-based clinical application for: clinical application for: • Running • Low Back • Knee • Walking • Functional • Hamstring Mar 2017 May 2017
Slide 27: Branding and Credibility
// 27 For personal use only BRANDING AND CREDIBILITY INSPIRING THE WORLD TO MOVE WELL™
Slide 28: Elite Sports Market: Working with the Innovators
// 28 ELITE SPORTS MARKET: WORKING WITH THE INNOVATORS For personal use only • Working with thought leaders • Optimising algorithms to meet market needs • Test market for future consumer product
Slide 29: Outlook
For personal use only Outlook // 29
Slide 30: Product Evolution: First Mover Advantage
// 30 PRODUCT EVOLUTION: FIRST MOVER ADVANTAGE For personal use only
Slide 31: World Leaders Using dorsaVi Technology
// 31 WORLD LEADERS USING dorsaVi TECHNOLOGY For personal use only • Unique insights coming from these commercial research projects • Potential for new IP and publications 75+ • 45,000 individual data sets and building daily COMMERCIAL RESEARCH PROJECTS • Medical device and pharmaceutical companies
Slide 32: Mizuno Running Solution
// 32 MIZUNO RUNNING SOLUTION For personal use only • Retail pilot program in the UK with sports shoe specialist Mizuno • Objective is to better match runners with the correct shoe and increase their sales revenue • Confirm viability of ViMove technology in a retail environment “The initial results
Slide 33: Upcoming Newsflow
// 33 UPCOMING NEWSFLOW For personal use only • Annuity revenue from OHS customers • Launch of mini-sensors into the clinical and sports markets • Launch of extensive platform changes and introduction of apps to clinical product • New OHS contracts with major corporates (US, UK & Australia) • Appoin
Slide 34: dorsaVi contact details
// 34 dorsaVi™ For personal use only Andrew Ronchi PhD (Eng), B.App.Sci (Physio) Chief Executive Officer Level 1, 120 Jolimont Road, East Melbourne, Victoria 3002 Office: +61 9652 2192 | Mobile: +61 417 882 267 ar@dorsaVi.com | dorsaVi.com